article Open AccessTop 1% cited

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

New England Journal of Medicine · 2016 · Vol. 375(4) · pp. 311–322

Steven P. Marso✉(The University of Texas Southwestern Medical Center)Gilbert H. Daniels(Massachusetts General Hospital)Kirstine Brown‐Frandsen(Novo Nordisk (Denmark))Peter Lommer Kristensen(Novo Nordisk (Denmark))Johannes F.E. Mann(Friedrich-Alexander-Universität Erlangen-Nürnberg)Michael A. Nauck(Ruhr University Bochum)Steven E. Nissen(Cleveland Clinic London)Stuart Pocock(London School of Hygiene & Tropical Medicine)Neil R Poulter(Imperial College London)Lasse Steen Ravn(Novo Nordisk (Denmark))William M. Steinberg(George Washington University)Mette Stockner(Novo Nordisk (Denmark))Bernard Zinman(Sinai Hospital)Richard M. Bergenstal(Park Nicollet Clinic)John B. Buse(University of North Carolina at Chapel Hill)

View via DOI Full-text PDF

Abstract

In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048.).

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Pancreatic function and diabetesLiraglutideType 2 diabetesMedicineInternal medicineDiabetes mellitusCardiologyEndocrinology

MeSH terms

LiraglutideAgedCardiovascular DiseasesDiabetes Mellitus, Type 2Double-Blind MethodFemaleGastrointestinal DiseasesHumansHypoglycemic AgentsMaleMiddle AgedMyocardial InfarctionTreatment OutcomeStroke